

Head office: 301.Aura Biplex, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail: compliance@sudarshanpharma.com Website: www.sudarshanpharma.com Board Line: + 91-22-42221111 / 42221116 (100 line) CIN: L51496MH2008PLC184997

SPIL/CS/SE/2024-2025/37

Date: 14th October 2024

To,

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828

BSE Trading Symbol: SUDARSHAN

ISIN: INEOOTV01015

Sub: Intimation for acquisition of the shares of Ishwari Healthcare Private Limited

Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure

Requirements) Regulations, 2015

Dear Sir / Madam.

Pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), this is to inform you that the Board of Directors of the Company have, on 14th October, 2024 inter-alia approved to acquire 2,09,100 equity shares of Rs.10/- each of Ishwari Healthcare Private Limited ('Ishwari Healthcare') (CIN: U85100MH2011PTC212867) equivalent to 51.00% of the paid up equity share capital of the Company and enter into Share Purchase Agreement. Upon completion of the acquisition, Ishwari Healthcare would become a subsidiary of the Company.

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given in Annexure A.

This is for your information and record.

Thanks & Regards,

Yours faithfully,

For, Sudarshan Pharma Industries Limited

Hemal Mehta

Chairman & Managing Director





Head office: 301.Aura Biplex, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail: compliance@sudarshanpharma.com **Website**: www.sudarshanpharma.com **Board Line**: + 91-22-42221111 / 42221116 (100 line) **CIN**: L51496MH2008PLC184997

Annexure-A.

Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given below:

SL NO	Details to be Provided	Information	
1	Name of the target entity, details in brief such as size, etc.	Name: Ishwari Healthcare Private Limited (As on 31 st March 2024) Authorised Share Capital: Rs.50,00,000/- Paid Up Share Capital: Rs.41,00,000/- Total Income: Rs.3,72,00,800/-	
2	Whether the acquisition would fall within related party transactions and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of the interest and details thereof and whether the same is done at 'arm's length'	No. The acquisition would not fall within the related party transactions. SPIL	
3	Industry to which the entity being acquired belongs.	Ishwari Healthcare Private Limited is in the business to produce, process, prepare, treat, disinfect, compound, formulate, mix, concentrate, pack, repack, refine, add, remove, pure, preserve, grade, freeze, distillate, boil, sterilize, improve, extract, buy, sell, resell, trade, import, export, barter, transport, store, forward, distribute, dispose, develop, research, discover, manipulate, market, supply and to act as agent, broker, adatia, representative, consultant, collaborator, stockist, liasioner, middleman, jobworker or otherwise to deal in all types of medical and surgical instruments and equipments goods, products, instruments, apparatus, and devices relating to all branches of medicine, surgery and healthcare including cardiology, ophthalmology and neurology, descriptions, specifications, strengths and applications of pharmaceutical, chemical and healthcare products of medicaments in all its branches such as allopathic, ayurvedic, homeopathic, herbal, unani, siddha, bio-chemi, naturopathy etc., used for treatment, cure and healthcare of human beings and animals and other allied goods and to do trading business by way of becoming manufacturers, buyers, sellers, important or products, distributors, stockists, retailers, whole	



Head office: 301.Aura Biplex, Premium Retail, Premises, 7, S.V.Road Boriwali (west) Mumbai - 400092 E-mail: compliance@sudarshanpharma.com Website: www.sudarshanpharma.com Board Line: + 91-22-42221111 / 42221116 (100 line) CIN: L51496MH2008PLC184997

			provider, handling and haulag Warehousemen, Transport healthcare product companies.	e contractors, handling goods, Agents and contractors for	
4		Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	of dealing in all types of medical, surgical instruments equipment, goods, products, instruments, apparatus and devices relating to all branches of medicine		
	5	Brief details of governmental or any regulatory approvals "required for the acquisition	Not Applicable		
7	6	Indicative time period for completion of the acquisition	31st October, 2024		
	7	Nature of Consideration whether	To be subscribed in cash.		
		Cash consideration or share swap and details of the same	ARMAWO		
	8	Cost of acquisition or the price at which the shares are acquired.	Rs.2,60,00,000/- only (Rupees Two Crores and Sixty Lakhs only)		
	9	Percentage of shareholding control acquired and /or number of shares acquired	2,09,100 equity shares of Rs.10/- each (51.00% of the paid-up share capital) of Ishwari Healthcare Private Limited.		
	10	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Ishwari Healthcare Private limited was incorporated on 31 January 2011. Ishwari Healthcare Private limited is a progressive & innovativ Company dedicated to serve world market by providin superior services, user-friendly and state-of-the-art healthcar disposables & devices conforming to international standards a competitive prices. Putting technology to the best us combined with the spirit of innovativeness and creativity Ishwari Healthcare Private limited provides world-class products to cater the needs of global customers more effectively and efficiently. Last 3 years' turnover details: Financial Year (Amount in Lakhs)		
			2023-2024 2022-2023 2021-2022	(Amount in Lakhs) 372.00 524.24 625.92	



Head office: 301.Aura Biplex, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail: compliance@sudarshanpharma.com Website: www.sudarshanpharma.com Board Line: + 91-22-42221111 / 42221116 (100 line) CIN: L51496MH2008PLC184997

Countries in which the acquired entity has presence: India, Nigeria, Benin, Sudan, Yemen, Zambia, Myanmar.

For, Sudarshan Pharma Industries Limited

Hemal Mehta Chairman & Managing Director

